SABRATEK CORP (SBTK) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SABRATEK CORP (SBTK)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DD™ who wrote ()	6/1/1999 9:33:00 AM
From: Know Genius	of 487

SAN FRANCISCO, May 28 (Reuters) - BancBoston Robertson Stephens said Friday it repeated a buy rating on Sabratek Corp. after the Food and Drug Administration granted the company clearance to market its saline ROCAP pre-filled flush syringes. Saline syringes account for 70 percent of ROCAP volume. "Clearly, the FDA's go-ahead for Sabratek's saline ROCAP syringes is excellent news for the company," said analyst Dr. Wade King. "Sabratek has maintained a state of manufacturing readiness in anticipation of this clearance. For the second quarter of 1999, we have forecast $1.2 million in ROCAP sales, which we believe is achievable. King also set a 1999 price target at $34, 25 times his year 2000 earnings per share estimate of $1.35. Currently, the stock is trading at 16.6 times the year 2000 estimate. Sabratek develops, makes and markets therapeutic and diagnostic products designed for use in the alternate-site healthcare market. Shares of Sabratek were trading up 1/16 to 22-1/2. ((--Chicago Equities News at 312 408 8787,

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next